TriSalus Life Sciences adds oncology expert to SAB

DENVER - TriSalus Life Sciences Inc. (NASDAQ:TLSI), an oncology company focusing on liver and pancreatic cancer treatments, has announced the appointment of Dr. Riad Salem to its Scientific Advisory Board (SAB). Dr. Salem, a notable figure in the field of interventional radiology, brings his expertise in radiological research and innovative treatment development to the company's advisory team.

Dr. Salem's career includes significant contributions to liver cancer treatment, particularly through his leadership in the LEGACY study, which highlighted the effectiveness of y90 radiotherapy. His appointment is expected to bolster TriSalus's efforts in advancing their novel immunotherapy, nelitolimod, and Pressure Enabled Drug Delivery (PEDD) technology.

TriSalus's CEO, Mary Szela, expressed enthusiasm for Dr. Salem's addition to the SAB, citing his alignment with the company's mission to enhance patient outcomes through data-driven approaches. Dr. Salem reciprocated this enthusiasm, emphasizing the need for improved treatments for complex liver and pancreatic cancers.

The company's PEDD technology, which includes FDA-cleared devices like the TriNav Infusion System and the Pancreatic Retrograde Venous Infusion System, aims to improve therapeutic delivery to tumors while reducing undesired effects on normal tissue. Nelitolimod, their investigational immunotherapeutic candidate, is designed to counteract the immunosuppressive environments of tumors, potentially improving the efficacy of existing immunotherapies.

Dr. Salem's role is particularly pivotal as TriSalus launches its DELIVER program, which seeks to provide comprehensive clinical data supporting the PEDD method and nelitolimod in challenging patient populations.

This news is based on a press release statement from TriSalus Life Sciences. The company is known for its disruptive drug delivery technology and clinical-stage investigational immunotherapy, aiming to improve therapeutic delivery to liver and pancreatic tumors. For more information about TriSalus Life Sciences and its technologies, please visit their official website.

In other recent news, TriSalus Life Sciences has made significant strides in its oncology sector. The company recently published research demonstrating a significant improvement in the delivery of therapeutic glass microspheres to liver tumors using its Pressure-Enabled Drug Delivery (PEDD) method. This method, applied through TriSalus's TriNav Infusion System, showed a 117% increase in penetration with lobar infusions and a 39% increase with selective infusions compared to traditional methods.

In the realm of financial analysis, TriSalus has been the subject of several analyst ratings. Oppenheimer initiated coverage with an Outperform rating, citing the company's potential in liver cancer treatment. Additionally, Jones Trading maintained a Buy rating based on the anticipated clinical benefits of its product Nelitolimod, and Canaccord Genuity also maintained its Buy rating, citing the company's growth prospects.

TriSalus's revenue, annualizing at approximately $30 million with a compound annual growth rate of 40-50%, was highlighted as a strong factor. The company has also secured a $50 million credit facility with healthcare investment firm OrbiMed, extending its cash runway through 2025.

In addition, TriSalus welcomed Liselotte Hyveled, a veteran in pharmaceutical research and development, to its Board of Directors. These developments underscore the company's potential for growth and strategic initiatives in the oncology sector.

InvestingPro Insights

TriSalus Life Sciences Inc. (NASDAQ:TLSI) has recently made a strategic move by appointing Dr. Riad Salem to its Scientific Advisory Board, which could potentially enrich the company's innovative approach to treating liver and pancreatic cancer. As the company welcomes Dr. Salem, investors and stakeholders are closely monitoring its financial health and market performance. The following insights from InvestingPro may provide a valuable perspective on the company's current status.

One of the notable InvestingPro Data metrics is the company’s impressive gross profit margin, which stands at 87.65% for the last twelve months as of Q2 2024. This indicates that TriSalus is highly efficient in its operations, retaining a substantial proportion of revenue after accounting for the cost of goods sold. This metric is particularly relevant as the company invests in its PEDD technology and nelitolimod, which may lead to increased operational costs.

However, despite the strong gross profit margins, TriSalus is quickly burning through cash, as indicated by an operating income margin of -212.06% for the same period. This suggests that the company's expenses significantly exceed its revenue, a situation that often necessitates careful financial management and may impact the company's ability to sustain long-term research and development efforts.

InvestingPro Tips highlight that the company's stock has taken a significant hit over the last week, with a 1-week price total return of -12.64% as of a recent date. This could reflect investor concerns over the company's cash burn rate and the challenging path to profitability, as analysts do not anticipate the company will be profitable this year.

For investors seeking a deeper analysis of TriSalus Life Sciences, additional InvestingPro Tips are available, providing more detailed insights into the company’s performance and potential investment opportunities. Currently, there are 10 more tips listed on InvestingPro, which can be accessed for a comprehensive understanding of the company's financial health and market position.

TriSalus's focus on developing innovative cancer treatments is a critical mission, and the financial metrics provided by InvestingPro offer a lens through which to assess the company's ability to continue its work effectively. As the company progresses, these insights may prove invaluable to those following its journey.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.